T1	Participants 242 276	patients with head-and-neck cancer
T2	Participants 300 549	Fifty patients were randomized to receive conventional radiotherapy (RT) (2-Gy fractions, 5 days weekly, to a total of 60-74 Gy, depending on the tumor localization and TNM classification) and carboplatin (90 mg/m(2) infusion once per week before RT
T3	Participants 552 653	Amifostine (300 mg/m(2)) was administered in the study group only 15-30 min before RT for 6-7.5 weeks
